Moderna CEO Bancel: Future Covid Vaccine Booster Will Likely Target Omicron Variant

Published by
ValueWalk

Following is the unofficial transcript of a CNBC interview with Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel on CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) today, Monday, January 10. Following are links to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Moderna CEO Bancel: Future Covid Vaccine Booster Will Likely Target Omicron VariantModerna CEO: We Can Supply Up To 3 Billion Covid Vaccine Booster Doses This YearBECKY QUICK: The annual J.P. Morgan HealthCare Conference begins today. It’s the industry’s largest healthcare investments symposium and it will be virtual once again t…

Read more

Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy SHANGHAI, China, and REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., […]

General Fusion achieves critical technology milestone for practical fusion power

Successful performance of plasma compression prototype confirms path to commercialization General Fusion’s plasma compression prototype VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — General Fusion announced today it has successfully achieved several aggressive performance goals of a prototype system for its Fusion Demonstration Plant (FDP). The company’s plasma compression prototype, located at its Vancouver, […]

2022 A4BET® Worldwide Domain & Trademark Sale

BEIJING and LONDON and PARIS and SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) — After overwhelming demand, creative offers and global inquires from it’s recent September 2021 billion dollar auction, A4BET® is announcing a time sensitive bidding process to acquire this rare, unique, valuable name. A4BET® covers everything from A-Z! The sale of A4BET® includes: […]

British Fishing Tackle & Bait Scales Order Fulfillment Processing 250% with Descartes Ecommerce WMS

CHIPPENHAM, United Kingdom, Jan. 10, 2022 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that UK-based sports and hobbies retailer Fishing Tackle & Bait has successfully transformed its international fulfillment capabilities with Descartes’ cloud-based ecommerce warehouse management solution (WMS). With Descartes, the multi-channel […]

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical […]

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral infection on the point-of-need platform MeMed Key® HAIFA, Israel; BOSTON, MA; January 10th, 2022 – MeMed, a leader in host response technologies, today announces a $93 million […]

Nyxoah Provides General Corporate Update

Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep […]